title: Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma.
abstract: Patients with hepatocellular carcinoma (HCC) receive a higher MELD score and may undergo liver transplantation (OLT) earlier compared to patients with cirrhosis, potentially decreasing waiting list mortality. However, post-OLT survival may be reduced by recurrence of HCC. We compared clinical outcomes between patients with HBV-cirrhosis and no HCC and patients with HBV-HCC. A total of 279 patients (HBV-cirrhosis = 183; HBV-HCC = 96) in the US HBV-OLT study were followed for a median of 30.2 months from listing. Patients with HCC were older, more likely to be Asian, and had less severe liver impairment than patients with HBV-cirrhosis. Despite a higher rate of OLT in patients with HCC (78.1% vs. 51.4%; P < 0.001), intention-to-treat (ITT) survival (73% vs. 78%) and survival without OLT (82% vs. 79%) at 5 years were similar for patients with and without HCC. Cox regression analysis identified higher albumin, lower MELD, no HCC at listing, and being transplanted to be associated with better ITT survival. Ninety-four patients with HCC (including 19 new HCC) and 75 with HBV-cirrhosis underwent OLT. Post-OLT survival (83% vs. 90%) and HBV recurrence (11% vs. 10%) at 3 years were similar, while disease (HBV and/or HCC) recurrence (19% vs. 10%; P = 0.043) was higher in patients with HBV-HCC vs. HBV-cirrhosis. Disease recurrence was the only independent predictor of post-OLT survival. In conclusion, despite more advanced liver disease and a lower rate of transplantation, ITT survival of patients listed for HBV-cirrhosis was comparable to those with HBV-HCC, possibly related to beneficial effects of antiviral therapy.
authors.affiliation: Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109-0362, USA.
authors.forename: Stephen N
authors.initials: SN
authors.lastname: Wong
authors.forename: K Rajender
authors.initials: KR
authors.lastname: Reddy
authors.forename: Emmet B
authors.initials: EB
authors.lastname: Keeffe
authors.forename: Steven-Huy
authors.initials: SH
authors.lastname: Han
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Gaglio
authors.forename: Robert P
authors.initials: RP
authors.lastname: Perrillo
authors.forename: Tram T
authors.initials: TT
authors.lastname: Tran
authors.forename: Timothy L
authors.initials: TL
authors.lastname: Pruett
authors.forename: Anna S F
authors.initials: AS
authors.lastname: Lok
mesh_terms: D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000601:surgery*; D004279:DNA, Viral / Q000097:blood; D003627:Data Interpretation, Statistical; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000150:complications / Q000601:surgery*; D006515:Hepatitis B virus / Q000235:genetics; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications / Q000601:surgery*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D009927:Tissue and Organ Procurement / Q000706:statistics & numerical data; D016896:Treatment Outcome; D014850:Waiting Lists
chemical_list: D004279:DNA, Viral